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INTRODUCTION
Infections due to antimicrobial resistant bacteria are difficult
to cure (1). Antimicrobial resistance can also lead to a delay in
the administration of appropriate drugs, and the drugs required
to treat resistant pathogens can be toxic (2). Antimicrobial
resistance has become a worldwide problem with the excep-
tion of a few countries in northern Europe (3). However, even
in Sweden, where resistant bacteria are rare, increases of ci-
profloxacin-resistant Escherichia coli and imipenem-resistant
Pseudomonas aeruginosa have been reported (4).
The prevalence of resistant bacteria varies significantly in
different countries as it is influenced by the amount of antimi-
crobial agents used. The major reasons for performing surveil-
lance are to determine the size of the problem, to see whether
resistance is increasing or not, to detect any previously un-
known types of resistance, and to determine whether any par-
ticular type of resistance is spreading or is associated with an
outbreak (1).
Antimicrobial resistance surveillance became increasingly
important given the wide spread dissemination of resistant
bacteria. Analysis of routine susceptibility data has some lim-
itations, which include its inaccuracy, but it does not require
much resource. Longitudinal studies of resistance trends are
considered most beneficial for the detection of subtle changes
in resistance (5). A previous nationwide surveillance in Korea
showed increasing resistance rates of Enterococcus faecium to van-
comycin, Enterobacteriaceae to fluoroquinolones, the 3rd gen-
eration cephalosporins, cephamycins and fluoroquinolones, and
P. aeruginosa and acinetobacters to carbapenems (6). It is hoped
that the Korean National Health Insurance Program, which
in 2001 abolished over-the-counter sales of antimicrobial agents
and started to scrutinize proper use of antimicrobial agents
at hospitals, has had some impact upon reducing resistant bac-
teria.
The aim of the surveillance in 2001was: to determine any
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Increasing Prevalence of Vancomycin-Resistant Enterococcus faecium,
Expanded-Spectrum Cephalosporin-Resistant Klebsiella pneumoniae,
and Imipenem-Resistant Pseudomonas aeruginosa in Korea: KONSAR
Study in 2001
The 5th year KONSAR surveillance in 2001 was based on routine test data at 30
participating hospitals. It was of particular interest to find a trend in the resistances of
enterococci to vancomycin, of Enterobacteriaceae to the 3rd generation cephalosporin
and fluoroquinolone, and of Pseudomonas aeruginosa and acinetobacters to carbapen-
em. Resistance rates of Gram-positive cocci were: 70% of Staphylococcus aureus
to oxacillin; 88% and 16% of Enterococcus faecium to ampicillin and vancomycin,
respectively. Seventy-two percent of pneumococci were nonsusceptible to penicillin.
The resistance rates of Enterobacteriaceae were: Escherichia coli, 28% to fluoro-
quinolone; Klebsiella pneumoniae, 27% to ceftazidime, and 20% to cefoxitin; and
Enterobacter cloacae, ≥40% to cefotaxime and ceftazidime. The resistance rates
of P. aeruginosa were 21% to ceftazidime, 17% to imipenem, and those of the acine-
tobacters were ≥61% to ceftazidime, aminoglycosides, fluoroquinolone and cotri-
moxazole. Thirty-five percent of non-typhoidal salmonellae were ampicillin resistant,
and 66% of Haemophilus influenzae were  -lactamase producers. Notable changes
over the 1997-2001 period were: increases in vancomycin-resistant E. faecium, and
amikacin- and fluoroquinolone-resistant acinetobacters. With the increasing preva-
lence of resistant bacteria, nationwide surveillance has become more important for
optimal patient management, for the control of nosocomial infection, and for the con-
servation of the newer antimicrobial agents.
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changing trends in the above-mentioned serious resistances
in particular, besides the common resistances at Korean Nation-
wide Surveillance of Antimicrobial Resistance (KONSAR)
hospitals in different locations, and to determine possible emer-
gence of new resistances.
MATERIALS AND METHODS
Data Collection
Routine susceptibility test data for major aerobic pathogenic
bacteria in 2001 were collected from 31 hospitals located in
8 cities/provinces in Korea. However, the data obtained from
30 hospitals were analyzed, excluding one hospital with poor
performance versus the WHO/CDC quality control program.
As did in the previous study (6), less than 20 isolates of a species
from a hospital was excluded from the analysis.
Main methods of susceptibility testing used were, the NCC-
LS disk diffusion test (7) by 21 hospitals and commercial broth
microdilution systems, i.e., Vitek (bioMerieux, Marcy l’ Etoile,
France) or MicroScan (Dade MicroScan Inc., West Sacramen-
to, CA, U.S.A.) by 9 hospitals. Methicillin-resistant staphy-
lococci were tested using oxacillin, and penicillin G-nonsus-
ceptible pneumococci were screened mainly by the oxacillin-
disk method (7).
Data analysis
Hospitals were divided into three groups according to loca-
tion and bed capacity (≥1,000 beds countrywide, <1,000
beds in Seoul, and <1,000 beds in non-Seoul). Resistance rates
did not include intermediates. The mean resistance rate in each
hospital group was calculated from the mean resistance rates
at each hospital, to minimize the influence of a large number
of isolates at some hospitals (8).
The resistance rates of some important organisms to certain
antimicrobial agents were compared to those of previous years.
However, the statistical significances of changes in resistance
were not determined, because this depends on the statistical
method used (8), and because the purpose of surveillance in-
cludes the detection of outbreaks of resistant infections (9).
RESULTS
The susceptibility data analyzed were of 169,032 isolates,
which consisted of 79,167 (46.8%) isolates of Gram-positive
cocci, and 89,865 (53.2%) isolates of Gram-negative bacilli.
Proportions of the organisms were: Staphylococcus aureus 24.1%,
coagulase-negative staphylococci 11.1%, Enterococcus faecalis
6.0%, E. faecium 3.8%, pneumococci 1.8%, E. coli 12.0%, Kleb-
siella pneumoniae 7.0%, Enterobacter cloacae 3.8%, Serratia marc-
escens 3.4%, non-typhoidal salmonellae 0.6%, acinetobacters
9.4%, P. aeruginosa 16.5%, and Haemophilus influenzae 0.4%.
The resistance rates of Gram-positive cocci are shown in Table
1. Those of S. aureus to oxacillin, erythromycin, and gentam-
icin were ≥70%, but the rates of coagulase-negative staphy-
lococci to these antimicrobial agents were somewhat lower.
The resistance rates of S. aureus to cotrimoxazole were lower
than that of coagulase-negative staphylococci (12% vs. 42%),
but were higher to ciprofloxacin (64% vs. 34%) and to tetra-
cycline (63% vs. 43%). Vancomycin-intermediate or -resis-
tant staphylococci were not present.
The rate of penicillin-nonsusceptible pneumococci was 72%,
and that of ciprofloxacin-resistance was 6%. The resistance
rates of E. faecium were much higher than those of E. faecalis to
ampicillin (88% vs. 2%), and to ciprofloxacin (88% vs. 43%),
but lower to tetracycline (23% vs. 81%). The vancomycin resis-
tance rates of E. faecium and E. faecalis were 16% and 1%, res-
pectively.
The resistance rates of Gram-negative bacilli are shown in
Table 2. Resistance rate of E. coli to ampicillin was 75%, and
to both piperacillin and cotrimoxazole ≥50%. Resistance rates
to other antimicrobial agents were: 9% to ceftazidime, 11%
to cefoxitin, 30% to gentamicin, and 28% to fluoroquinolone.
Twenty-seven per cent and 20% of K. pneumoniae were resis-
tant to ceftazidime and cefoxitin, respectively, and 12% were
Antimicrobial agents
Resistance rate (%)
S. aureus
(n=40,824)
Coagulase-negative staphy-
lococci (n=18,779)
S. pneumoniae
(n=3,071)
E. faecalis
(n=10,076)
E. faecium
(n=6,417)
Oxacillin 70 69 72 -* -
Ampicillin/penicillin 97 92 - 28 8
Erythromycin 74 58 79 --
Cotrimoxazole 12 42 -- -
Tetracycline 63 43 - 81 23
Gentamicin 70 57 -- -
Ciprofloxacin 64 34 6 43 88
Vancomycin 0 0 - 11 6
*Not tested.
Table 1. Antimicrobial resistance rates of Staphylococcu species, S. pneumoniae and Enterococcus species10 K. Lee, S.-J. Jang, H.J. Lee, et al.
resistant to amikacin. Of the E. cloacae isolates, ≥40% were
resistant to cefotaxime and ceftazidime, and 40% were to to-
bramycin. Imipenem resistance rates of E. cloacae and S. mar-
cescens were 0.4% and 0.6%, respectively. The resistance rates
of S. marcescens to cefoperazone-sulbactam and amikacin, at
15% and 22%, respectively, were the highest among Enter-
obacteriaceae species analyzed. The resistance rates of P. aerugi-
nosa to ceftazidime and cefotaxime were 21% and 57%, respec-
tively. The resistance rates to imipenem and amikacin 17%
and 26%, respectively. Of the acinetobacters, ≥65% were
resistant to piperacillin, cefotaxime, ceftazidime, and aztreon-
am. Cefepime resistance rate of 52% was the highest among
Gram-negative bacilli. Also, ≥61% of the isolates were resis-
tant to aminoglycosides, fluoroquinolone and cotrimoxazole.
The imipenem resistance rate of all isolates was 6%.
Among the 990 isolates of non-typhoidal salmonellae, 35%
were resistant to ampicillin, and 4% to cotrimoxazole, but none
were resistant to fluoroquinolone. In the case of H. influenzae,
some hospitals tested ampicillin susceptibility, while others
tested  -lactamase production, and still others tested both.
Among the 699 isolates of H. influenzae, 64% were ampicillin
resistant and 66% were  -lactamase producers.
During the period 1997-2001, the resistance rates of S. aureus
to oxacillin and erythromycin remained similar (Fig. 1). Peni-
cillin-nonsusceptible pneumococci declined slightly from 75%
to 72%, whereas ampicillin-resistant E. faecium increased steadi-
Antimicrobial agents
Resistance rate (%)
E. coli
(n=20,332)
K. pneumoniae
(n=11,856)
E. cloacae
(n=6,447)
S. marcescens
(n=5,701)
P. aeruginosa
(n=27,940)
Acinetobacter spp.
(n=15,900) 
Ampicillin 75 -* ----
Ampicillin-sulbactam 32 33 --- 45
Cephalothin 39 36 ----
Cefotaxime 9 18 40 36 57 73
Ceftazidime 9 27 44 26 21 65
Cefepime 5 9 7 11 20 52
Aztreonam 7 24 35 25 22 76
Cefoperazone-sulbactam 3 7 9 15 28 18
Cefoxitin 11 20 ----
Cefotetan 3 7 ----
Piperacillin 60 42 58 45 33 66
Piperacillin-tazobactam 5 12 24 22 24 48
Imipenem 0 0 0.4 0.6 17 6
Amikacin 6 12 12 22 26 61
Gentamicin 30 26 37 42 40 70
Tobramycin 25 30 40 23 37 69
Fluoroquinolone
� 28 10 10 19 40 65
Cotrimoxazole 50 22 35 34 - 62
Tetracycline 59 30 30 86 - 74
*Not tested. 
� Mostly tested by using ciprofloxacin, but some hospitals used ofloxacin or levofloxacin.
Table 2. Antimicrobial resistance rates of Enterobacteriaceae, P. aeruginosa and Acinetobacter spp.
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Fig. 1. The trend of resistance of Staphylococcus isolates to oxacillin
and erythromycin, and Enterococcus to ampicillin, and of penicillin
G-nonsusceptible S. pneumoniae. OXA, oxacillin; ERY, erythromycin;
AMP, ampicillin; PEN, penicillin G; R, resistant; NS, nonsuscepti-
ble; SAU, S. aureus; CNS, coagulase-negative Staphylococcus;
EFM, E. faecium; SPN, S. pneumoniae.
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ly from 70% to 88%. Vancomycin-resistant E. faecium isolates
increased at all hospital groups: from 2% to 16% at large hos-
pital group, from 2% to 19% at the Seoul medium hospital
group, and from 7% to 13% at the non-Seoul medium hos-
pital group (Fig. 2).
During the 1997-2001 period, cefoxitin-resistant K. pneu-
moniae increased from 16% to 20%, and ampicillin-resis-
tant H. influenzae from 58% to 64% (Fig. 3). The amikacin
resistance rate of P. aeruginosa declined slightly from 33% to
26%, while that of acinetobacters gradually increased from
50% to 61%. The resistance rates of acinetobacters to fluoro-
quinolone rose from 56% to 65% (Fig. 4), while the rates to
imipenem remained to be 5% to 6% (Fig. 3). Ceftazidime-
and imipenem-resistant P. aeruginosa were present in all hos-
pital groups (Fig. 5).
DISCUSSION
The surveillance of resistance is an important part of mod-
ern clinical microbiology (5), but surveillance methods are
considered often inappropriate (1). The surveillance, which is
based on collecting data from each laboratory has many prob-
lems due to the different methods used for species identifica-
tion and for susceptibility testing. More accurate results can
be obtained if isolates are collected and tested at a central lab-
oratory (5), but this method is very expensive.
Current KONSAR program consists of two different forms
of surveillance: one is the analysis of routine susceptibility test
data, which were determined by individual participating hos-
pitals, i.e., this study, and the other is the determination of
the prevalence of certain resistances in isolates collected from
participants, e.g., the study on metallo- -lactamase-produc-
ing strains (10).
Both the necessity and the limitations of surveillance were
discussed in a previous study (6). It is difficult to distinguish
between community- and nosocomially-acquired pathogens,
although their resistance rates differ markedly. However, some
organisms, such as methicillin-resistant staphylococci, van-
comycin-resistant enterococci, P. aeruginosa and acinetobacters
are typical nosocomial pathogens, while non-typhoidal salmo-
nellae are mostly community-acquired pathogens.
The high proportion of S. aureus (24.1%) among the iso-
lates tested in the present study indicates its continued impor-
tance. Methicillin-resistant S. aureus (MRSA) is one of the typ-
ical nosocomial pathogens (11). The proportion of MRSA and
methicillin-resistant coagulase-negative staphylococci, 70%
and 69%, respectively, were similar to those reported for 1999
and 2000 (Fig. 1). MRSA is also prevalent in Japan. Surveil-
lance in 1998-2000 in Kinki, Japan, showed the proportion
of MRSA was approximately 60% (12).
The more active drug against MRSA remained to be cot-
rimoxazole except for vancomycin, but the rate of 12% was
much higher one than the 1% found in Japan. Two isolates
of true vancomycin-resistant S. aureus were reported in the
United States in 2002 (13, 14). No vancomycin-resistant S.
aureus were recognized in the present study.
The penicillin-nonsusceptible rate of pneumococci decreased
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Fig. 3. Trend of resistance of E. coli and H. influenzae isolates to
ampicillin, K. pneumoniae to cefoxitin, P. aeruginosa to amikacin,
and Acinetobacter spp. to amikacin and imipenem. AMP, ampicillin;
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slightly from 78% in 1999 to 72% in 2001. A reduction in
penicillin-nonsusceptible isolates may be the result of the abo-
lition of over-the-counter sales of common antimicrobial agents
in 2001. It will be interesting to observe whether this declin-
ing trend continues. In Japan, the proportion of penicillin-non-
susceptible pneumococci, by the broth microdilution method,
was 65% in 1998 and 81% in 2000 (12). We should know
that the proportions were based on breakpoint for the treat-
ment of meningitis (7). Therefore, pneumonia caused by peni-
cillin-intermediate isolates may respond to penicillin therapy
(15). Pneumococci cause community-acquired lower respira-
tory tract infections more frequently than meningitis.
The ampicillin-resistant rate of E. faecalis, 1%, was slight-
ly lower than the 2% found in 2000, though still higher than
the <1% found at the coordinating laboratory of the KON-
SAR program. It was considered that ampicillin-resistant E.
faecalis was due to misidentification of the species (1). These
indicate the need to retest the species when an E. faecalis iso-
late shows resistance to ampicillin.
Vancomycin resistance rate of E. faecium in 2001 remained
similar to those in 2000 at large- and medium-hospital groups
in Seoul. Although the rate at the non-Seoul medium-hospi-
tal group declined from 24% in 2000 to 13% in 2001 (Fig.
2), vancomycin-resistant E. faecium seemed to be established
in all hospital groups, as was at the coordinating hospital (16).
It is a concern that once a resistance gene has became accumu-
lated to an environment, it is impossible to eliminate them
(17).
The ampicillin resistance rate of E. coli did increase further
and that of H. influenzae increased only slightly. Ampicillin
had been a commonly used drug because it was available with-
out prescription, but currently no antimicrobial agent can be
bought without a prescription since 2001. It is interesting
to see the future surveillance could show a downward trend
again. In the present study, 64% of the H. influenzae isolates
were resistant to ampicillin and the proportion of  -lactamase
producers was similar. The proportion of  -lactamase-produc-
ing isolates in the United States was 36%, while that was only
3% in Japan. In a European study (18), the prevalence of  -
lactamase producers varied from 8.1% to 34.8% depending
on countries. It is interesting that in Japan 39.6% of the iso-
lates were  -lactamase-negative ampicillin-resistant (BLNAR)
strains (19).
The resistance rates of non-typhoidal salmonellae, i.e., 35%
to ampicillin, 4% to cotrimoxazole and none to ciprofloxacin,
were similar to those reported in 2000 (6). When empirical
antimicrobial treatment of non-typhoidal salmonellae infec-
tion is required (20), cotrimoxazole or ciprofloxacin should
be appropriate first-line drugs in Korea. In the present study,
0.4% of non-typhoidal salmonellae were resistant to the 3rd
generation cephalosporin. Further study is required to deter-
mine whether extended-spectrum  -lactamase (ESBL)-pro-
ducing isolates are present. In a Korean hospital, ESBL-pro-
ducing non-typhoidal salmonellae were detected as early as
1995 (21).
Fluoroquinolones are increasingly used, as they are one of
the three major broad-spectrum classes of antimicrobial agents
(22). Fluoroquinolone resistance rate of E. coli gradually rose
from 24% in 1997 to 28% in 2001. The rate of acinetobacters,
65% was only slightly lower than that of the 70% in 2000 (6).
Expanded-spectrum cephalosporins are ineffective for the
treatment of infections caused by ESBL-producing isolates of
E. coli and K. pneumoniae, although they may be inhibited by
low concentrations of these drugs (23). It was reported that
bacteremic patients with ESBL-producing K. pneumoniae had
higher initial treatment failure rates than those with non-ESBL-
producing isolates (24). Also, the cefoxitin resistance rate 20%
of K. pneumoniae suggests plasmid-mediated AmpC  -lacta-
mase production (25). Therefore, ceftazidime resistance rates
cannot reflect the proportion of ESBL producers, although
high prevalence of ESBL-producing K. pneumoniae has been
reported in Korea (26). Cephamycins, such as cefoxitin, are
active against ESBL-producing isolates, but plasmid-medi-
ated AmpC  -lactamase-producing isolates are resistant not
only to all cephalosporins but also to cephamycins.
Carbapenems are very useful drugs as they are stable to hydro-
lysis even to ESBL- and AmpC  -lactamases (27). Although
VIM-2 metallo- -lactamase-producing S. marcescens and E.
cloacae have been reported (28, 29), the imipenem resistance
rates of E. cloacae and S. marcescens were low (0.4% and 0.6%,
respectively), suggesting that carbapenem-resistant Enterobac-
teriaceae are rare. The imipenem resistance rates of P. aerugi-
nosa to ceftazidime and imipenem remained similar in all hos-
pital groups (Fig. 5). In another study about 9% of imipenem-
resistant P. aeruginosa were due to the production of acquired
metallo- -lactamases (30). Acinetobacters are often multidrug
resistant. At a hospital in India, 29% of acinetobacters iso-
lated in 1996-1998 were resistant to imipenem, though the
hospital did not use imipenem at that time (31). In our pre-
sent study, the imipenem resistance rate of acinetobacters re-
mained similar (Fig. 3). However, the imipenem resistance
rate rose to 13% in 2002 at the coordinating laboratory. Anoth-
er study showed that approximately 11.4% and 14.2% of
imipenem-nonsusceptible isolates possessed the VIM-2 or
the IMP-1 metallo- -lactamase gene (10). We consider that
close observation of this trend is necessary.
Given the increase in the prevalence of resistant bacteria, the
empirical selection of antimicrobial agents becomes increas-
ingly difficult and rapid microbiological testing increasingly
crucial. As was found in the previous study, some laboratories
tested susceptibility to too few antimicrobial classes (data not
shown). Diagnostic bacteriology results cannot be obtained
immediately, but clinical microbiologists should remember
that early results only can aid the appropriate management of
patients, and consequently reduce emergence and the spread
of resistance. It was reported that early preliminary microbi-
ology results of blood stream infection had a greater impact
on antimicrobial management than susceptibility data (32).Antimicrobial Resistance Surveillance of Bacteria in 2001 in Korea 13
In conclusion, methicillin-resistant staphylococci, penicillin-
nonsusceptible pneumococci, ampicillin-resistant E. faecium
and H. influenzae, and expanded-spectrum cephalosporin-resis-
tant Gram-negative bacilli remain prevalent. Vancomycin-resis-
tant E. faecium, fluoroquinolone-resistant Gram-negative bacil-
li, and imipenem-resistant P. aeruginosa are increasing at all
groups of hospitals. Given this increasing resistance, not only
rapid and accurate routine susceptibility testing, but also the
nationwide resistance surveillance become even more impor-
tant for optimal patient management, the control of nosoco-
mial infection, and eventually to conserve newer antimicro-
bial agents.
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